Literature DB >> 8364536

Characterization of a human alpha 1-antitrypsin null allele involving aberrant mRNA splicing.

V E Laubach1, W J Ryan, M Brantly.   

Abstract

alpha 1-Antitrypsin (alpha 1AT) is a major protease inhibitor present in high concentrations in the plasma. Inheritance of alpha 1AT deficiency or null alleles (alleles associated with no detectable serum alpha 1AT) is associated with an increased risk for emphysema. In contrast to beta zero-thalassemia variants in which RNA splicing and promoter mutations constitute more than 40% of beta zero-thalassemia variants, all nine alpha 1AT null variants identified are the result of mutations involving the protein coding region of the alpha 1AT gene. During routine screening of individuals applying for enrollment in the USA alpha 1AT Deficiency Registry we identified an individual with emphysema and a Protease Inhibitor (PI*) type heterozygous for a novel alpha 1AT null allele. Direct DNA sequencing of this individual's alpha 1AT alleles demonstrated one normal and one novel allele, designated PI*QOwest, characterized by a single G-->T base substitution at position 1 of intron II, a highly conserved nucleotide position in vertebrate splice donor sites. Metabolic labeling of NIH-3T3 cells transfected with a plasmid vector containing an alpha 1AT minigene with the QOwest mutation demonstrated an absence of detectable immunoprecipitable alpha 1AT confirming that the G-->T mutation is responsible for the observed null phenotype. QOwest alpha 1AT minigene transfected cells expressed 25-100 fold less alpha 1AT mRNA than a normal control. DNA sequencing of polymerase chain reaction amplified mRNA obtained from transfected cells demonstrated the use of a cryptic splice site 84 bases upstream from the normal splice site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364536     DOI: 10.1093/hmg/2.7.1001

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

1.  Intrinsic differences between authentic and cryptic 5' splice sites.

Authors:  Xavier Roca; Ravi Sachidanandam; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

2.  Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency.

Authors:  N Novoradovskaya; J Lee; Z X Yu; V J Ferrans; M Brantly
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

Review 3.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

4.  Identification and characterisation of eight novel SERPINA1 Null mutations.

Authors:  Ilaria Ferrarotti; Tomás P Carroll; Stefania Ottaviani; Anna M Fra; Geraldine O'Brien; Kevin Molloy; Luciano Corda; Daniela Medicina; David R Curran; Noel G McElvaney; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

5.  Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid.

Authors:  Beatriz Lara; Maria Teresa Martínez; Ignacio Blanco; Cristina Hernández-Moro; Eladio A Velasco; Ilaria Ferrarotti; Francisco Rodriguez-Frias; Laura Perez; Irene Vazquez; Javier Alonso; Manuel Posada; Beatriz Martínez-Delgado
Journal:  Respir Res       Date:  2014-10-07

6.  An RNA structure-mediated, posttranscriptional model of human α-1-antitrypsin expression.

Authors:  Meredith Corley; Amanda Solem; Gabriela Phillips; Lela Lackey; Benjamin Ziehr; Heather A Vincent; Anthony M Mustoe; Silvia B V Ramos; Kevin M Weeks; Nathaniel J Moorman; Alain Laederach
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

7.  Molecular diagnosis of alpha1-antitrypsin deficiency: A new method based on Luminex technology.

Authors:  Stefania Ottaviani; Valentina Barzon; Amaya Buxens; Marina Gorrini; Amaia Larruskain; Rachid El Hamss; Alice M Balderacchi; Angelo G Corsico; Ilaria Ferrarotti
Journal:  J Clin Lab Anal       Date:  2020-03-17       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.